{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:56:08Z","timestamp":1795042568492,"version":"4.10.2"},"reference-count":65,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor that induces the expression of lytic EBV BGLF4 protein kinase in EBV+ tumor cells, activating ganciclovir via phosphorylation, resulting in tumor cell apoptosis. This phase 1b\/2 study investigated the combination of nanatinostat with valganciclovir in patients aged \u226518 years with EBV+ lymphomas relapsed\/refractory to \u22651\u00a0prior systemic therapy with no viable curative treatment options. In the phase 1b part, 25 patients were enrolled into 5 dose escalation cohorts to determine the recommended phase 2 dose (RP2D) for phase 2 expansion. Phase 2 patients (n\u00a0= 30) received RP2D (nanatinostat 20\u00a0mg daily, 4\u00a0days per week with valganciclovir 900\u00a0mg orally daily) for 28-day cycles. The primary end points were safety, RP2D determination (phase 1b), and overall response rate (ORR; phase 2). Overall, 55 patients were enrolled (B\u2013non-Hodgkin lymphoma [B-NHL], [n\u00a0= 10]; T-cell\/natural killer cell-NHL, [n\u00a0= 21]; classical Hodgkin lymphoma, [n\u00a0= 11]; and immunodeficiency-associated lymphoproliferative disorders, [n\u00a0=\u00a013]). The ORR was 40% in 43 evaluable patients (complete response rate [CRR], 19% [n\u00a0=\u00a08]) with a median duration of response of 10.4\u00a0months. For T-cell\/natural killer cell-NHL (n\u00a0= 15; all refractory to the last prior therapy), the ORR\/CRR ratio was 60%\/27%. The most common adverse events were nausea (38% any grade) and cytopenia (grade 3\/4 neutropenia [29%], thrombocytopenia [20%], and anemia [20%]). This novel oral regimen provided encouraging efficacy across several EBV+ lymphoma subtypes and warrants further evaluation; a confirmatory phase 2 study (NCT05011058) is underway. This phase 1b\/2 study is registered at www.clinicaltrials.gov as #NCT03397706.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010330","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T10:00:41Z","timestamp":1690970441000},"page":"6339-6350","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0615","authenticated-orcid":false,"given":"Bradley","family":"Haverkos","sequence":"first","affiliation":[{"name":"1Division of Hematology, University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-5344","authenticated-orcid":false,"given":"Onder","family":"Alpdogan","sequence":"additional","affiliation":[{"name":"2Division of Hematologic Malignancies and Hematopoetic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-4853","authenticated-orcid":false,"given":"Robert","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"3The Ohio State University James Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Brammer","sequence":"additional","affiliation":[{"name":"3The Ohio State University James Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"4John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Capra","sequence":"additional","affiliation":[{"name":"5Centro Integrado de Hematologia e Oncologia - Hospital M\u00e3e de Deus, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-9841","authenticated-orcid":false,"given":"Elizabeth A.","family":"Brem","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Deptartment of Medicine, University of California, Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Nair","sequence":"additional","affiliation":[{"name":"7Mid Florida Hematology and Oncology Center, Orange City, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Hospital A Benefic\u00eancia Portuguesa, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2821","authenticated-orcid":false,"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Hospital das Cl\u00ednicas da Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"10University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[{"name":"11Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Young","sequence":"additional","affiliation":[{"name":"12Ronald Reagan UCLA Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-3305","authenticated-orcid":false,"given":"Susan","family":"Spruill","sequence":"additional","affiliation":[{"name":"13Applied Statistics and Consulting, Spruce Pine, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afton","family":"Katkov","sequence":"additional","affiliation":[{"name":"14Viracta Therapeutics, Inc, Cardiff, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McRae","sequence":"additional","affiliation":[{"name":"14Viracta Therapeutics, Inc, Cardiff, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor","family":"Royston","sequence":"additional","affiliation":[{"name":"14Viracta Therapeutics, Inc, Cardiff, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[{"name":"14Viracta Therapeutics, Inc, Cardiff, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rojkjaer","sequence":"additional","affiliation":[{"name":"14Viracta Therapeutics, Inc, Cardiff, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-023X","authenticated-orcid":false,"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"2Division of Hematologic Malignancies and Hematopoetic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"12","key":"2023102417105907400_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"2023102417105907400_bib2","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"issue":"4","key":"2023102417105907400_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A\u00a0review of human carcinogens--part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023102417105907400_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human viral oncogenesis: a cancer hallmarks analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"key":"2023102417105907400_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"2023102417105907400_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"2023102417105907400_bib7","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Heal"},{"issue":"10","key":"2023102417105907400_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nri1201","article-title":"B\u00a0cells under influence: transformation of B cells by Epstein-Barr virus","volume":"3","author":"K\u00fcppers","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2023102417105907400_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023102417105907400_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semcancer.2009.07.004","article-title":"Burkitt\u2019s lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology","volume":"19","author":"Rowe","year":"2009","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2023102417105907400_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11899-015-0292-z","article-title":"The Epstein-Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment","volume":"10","author":"Gru","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2023102417105907400_bib12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Malpica","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"2023102417105907400_bib13","first-page":"11429","article-title":"Clinicopathological characteristics and prognostic analysis of epstein-barr virus-positive lymphoma: a meta-analysis","volume":"9","author":"Ding","year":"2016","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"2023102417105907400_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/ijc.30566","article-title":"Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas","volume":"140","author":"Haverkos","year":"2017","journal-title":"Int J Cancer"},{"issue":"16","key":"2023102417105907400_bib15","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","article-title":"Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified","volume":"5","author":"Bourbon","year":"2021","journal-title":"Blood Adv"},{"key":"2023102417105907400_bib16","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"2023102417105907400_bib17","doi-asserted-by":"crossref","first-page":"753366","DOI":"10.3389\/fviro.2021.753366","article-title":"Oncogenic viruses as entropic drivers of cancer evolution","volume":"1","author":"Tempera","year":"2021","journal-title":"Front Virol"},{"issue":"1732","key":"2023102417105907400_bib18","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr virus-associated lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"3","key":"2023102417105907400_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ejh.13274","article-title":"The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma","volume":"103","author":"Keane","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"2023102417105907400_bib20","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"2023102417105907400_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2245","article-title":"The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients","volume":"35","author":"Okamoto","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"2023102417105907400_bib22","doi-asserted-by":"crossref","first-page":"e0199398","DOI":"10.1371\/journal.pone.0199398","article-title":"Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: a meta-analysis","volume":"13","author":"Gao","year":"2018","journal-title":"PLoS One"},{"issue":"13","key":"2023102417105907400_bib23","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"issue":"18","key":"2023102417105907400_bib24","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"2023102417105907400_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/CMAR.S292293","article-title":"The clinical features and survival outcome of 107 newly diagnosed advanced stage extranodal NK\/T-cell lymphoma cases: a triple-center study","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"20","key":"2023102417105907400_bib26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2023102417105907400_bib27","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023102417105907400_bib28","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp Mol Med"},{"key":"2023102417105907400_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcancer.2014.01.003","article-title":"Epigenetic regulation of EBV persistence and oncogenesis","volume":"26","author":"Tempera","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2023102417105907400_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int J Cancer"},{"issue":"18","key":"2023102417105907400_bib31","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023102417105907400_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2006.03.022","article-title":"Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir","volume":"247","author":"Jung","year":"2007","journal-title":"Cancer Lett"},{"issue":"1","key":"2023102417105907400_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcmd.2006.10.008","article-title":"Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents","volume":"38","author":"Ghosh","year":"2007","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2023102417105907400_bib34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2023102417105907400_bib35","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A\u00a0phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2023102417105907400_bib36","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1158\/1078-0432.CCR-17-2685","article-title":"Complete and durable responses in primary central nervous system posttransplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab, and dexamethasone","volume":"24","author":"Dugan","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023102417105907400_bib37","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","article-title":"A\u00a0phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors","volume":"18","author":"Banerji","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2023102417105907400_bib38","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood.V114.22.4754.4754","article-title":"Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas","volume":"114","author":"Faller","year":"2009","journal-title":"Blood"},{"issue":"27","key":"2023102417105907400_bib39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023102417105907400_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood-2021-152603","article-title":"Nanatinostat (Nstat) and valganciclovir (VGCV) in relapsed\/refractory (R\/R) Epstein-Barr virus-positive (EBV\u00a0+) lymphomas: final results from the phase 1b\/2 VT3996-201 Study","volume":"138","author":"Haverkos","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023102417105907400_bib41","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","article-title":"Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS","volume":"107","author":"Wai","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"2023102417105907400_bib42","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1080\/10428194.2018.1452208","article-title":"Single-agent panobinostat for relapsed\/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi","volume":"59","author":"Zaja","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2023102417105907400_bib43","doi-asserted-by":"crossref","first-page":"576391","DOI":"10.3389\/fcell.2020.576391","article-title":"Recent update of HDAC inhibitors in lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2023102417105907400_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023102417105907400_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023102417105907400_bib46","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2023102417105907400_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00001622-200109000-00008","article-title":"Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies","volume":"13","author":"Faller","year":"2001","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2023102417105907400_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2023102417105907400_bib49","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","article-title":"Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas","volume":"78","author":"Feng","year":"2004","journal-title":"J\u00a0Virol"},{"issue":"10","key":"2023102417105907400_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/cgt.2011.51","article-title":"Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK\/ganciclovir","volume":"18","author":"Ladd","year":"2011","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"2023102417105907400_bib51","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1073\/pnas.96.15.8699","article-title":"Herpes simplex virus thymidine kinase\/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases","volume":"96","author":"Beltinger","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2023102417105907400_bib52","first-page":"5781","article-title":"Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in\u00a0vitro and in\u00a0vivo: a potential method for treating EBV-positive malignancies","volume":"60","author":"Westphal","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"2023102417105907400_bib53","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"2023102417105907400_bib54","doi-asserted-by":"crossref","first-page":"e004080","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J\u00a0Immunother cancer"},{"issue":"2","key":"2023102417105907400_bib55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1309\/MMAU-0QYH-7BHA-W8C2","article-title":"Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma","volume":"117","author":"Gulley","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2023102417105907400_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/his.13197","article-title":"Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells","volume":"71","author":"Ohashi","year":"2017","journal-title":"Histopathology"},{"issue":"7","key":"2023102417105907400_bib57","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V80.7.1804.1804","article-title":"Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type","volume":"80","author":"Anagnostopoulos","year":"1992","journal-title":"Blood"},{"issue":"8","key":"2023102417105907400_bib58","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1080\/10428194.2018.1563690","article-title":"Differential clinical significance of pre-interim-and post-treatment plasma Epstein-Barr virus DNA load in NK\/T-cell lymphoma treated with P-GEMOX protocol","volume":"60","author":"Wang","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2023102417105907400_bib59","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type","volume":"118","author":"Suzuki","year":"2011","journal-title":"Blood"},{"key":"2023102417105907400_bib60","doi-asserted-by":"crossref","first-page":"594692","DOI":"10.3389\/fonc.2020.594692","article-title":"Superiority of Epstein-Barr virus DNA in the plasma over whole blood for prognostication of extranodal NK\/T cell lymphoma","volume":"10","author":"Ha","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2023102417105907400_bib61","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","article-title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023102417105907400_bib62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2016002618","article-title":"Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma","volume":"1","author":"Welch","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2023102417105907400_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0463.2010.02685.x","article-title":"Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients","volume":"119","author":"Spacek","year":"2011","journal-title":"APMIS"},{"issue":"3","key":"2023102417105907400_bib64","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3109\/10428194.2015.1072766","article-title":"Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma","volume":"57","author":"Tisi","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023102417105907400_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A\u00a0prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6339\/2085305\/blooda_adv-2023-010330-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6339\/2085305\/blooda_adv-2023-010330-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:20:54Z","timestamp":1698153654000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6339\/497221\/Targeted-therapy-with-nanatinostat-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":65,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010330","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]}}}